INTRODUCTION
Cystic fibrosis (CF) affects a number of epithelial-lined organs, the most important being the lungs, responsible for the majority of the morbidity in this disease and eventually the usual cause of death from respiratory failure. This lung disease results from impaired airway defence against infection; bacterial colonization usually occurs in childhood and progresses to episodes of overt infection and subsequent lung damage.
The CF gene is present on the long arm of chromosome 7 and was cloned in 19891. The protein coded for, cystic fibrosis transmembrane conductance regulator (CFTR), functions as a chloride channel in the apical membrane of respiratory and intestinal epithelial cells. Elevation of the second messenger cAMP within the cell results in opening of the channel to allow chloride secretion from the cell on to the mucosal surface. Water will follow this chloride movement by osmosis, and this provides a means by which this surface can be hydrated. In turn this is likely to be important in the airways in the process of mucociliary clearance. Thus, inhaled particles and bacteria are removed from the airways by the synchronized beating of cilia on the mucosal surface of the epithelial cells. These cilia beat in a thin fluid layer which allows for maximal efficiency of this process. Chloride secretion is likely to provide an important contribution to this layer. Patients with CF mutations in the CFTR gene have reduced or absent cAMP-mediated chloride secretion in all affected organs including the airways2. This is because the abnormal protein is either mislocalized, never reaching the mucosal surface, or it does reach its intended target but functions with markedly reduced efficiency. The likely net result is that water movement is also reduced leading to a suboptimal periciliary layer in the airways. In turn this will result in impaired mucociliary clearance, reduced clearance of bacteria and the resulting repeated infections which predispose to lung damage. Sodium absorption from the airway surface is also abnormal in these patients, being increased 2-3 fold. The link between the former basic defect and the secondary sodium abnormality is presently unclear. However, since water will again follow the sodium movement, this second abnormality will also tend to dehydrate the airway surface liquid exacerbating the problem.
GENE THERAPY
The most obvious, and perhaps elegant, way of treating CF would be to introduce a new normal copy of the CFTR gene into the respiratory tract of these patients. Following the identification of the CF gene this has become a realistic possibility, and this was given further recent impetus with the production of several mouse models for CF36. We7 and others8 have therefore assessed whether CFTR gene transfer into these CF mice could correct the ion transport abnormalities present. We devised a nebulizer system for delivering agents to the respiratory tract of mice. This was validated using the dye methylene blue as well as the reporter gene /3-galactosidase, demonstrating that up to approximately 40% of lower airway epithelial cells could be transfected using the cationic liposome DC-Cholesterol: DOPE as the gene transfer agent. We also devised a technique for delivering DNA:liposome complexes to the large intestine of these animals. Again this was validated using methylene blue; given the high levels of endogenous 13-galactosidase present in this organ, reporter gene validation was not undertaken.
Subsequently, CFTR cDNA-DC-Cholesterol complexes were administered to exon 10 insertional CF mice and assays for mRNA and correction of the ion transport defects undertaken. With regard to the former, each of the eight treated animals showed evidence for expression of human specific CFTR mRNA; no expression was seen in the placebo treated or untreated animals. All assays were conducted in a blinded manner with respect to the treatment received. Importantly, however, there was marked variability, both within and between animals, with respect to CFTR mRNA expression. In vivo analysis of the nasal ion transport properties of the treated animals showed that there was restoration of approximately 50% of the deficit between CF and wild-type animals in the chloride abnormality. Interestingly, no improvement was seen in the sodium defect. As for the mRNA studies, marked variability was seen, some animals showing complete correction of the chloride defect and others little or none. Very similar results were seen in the trachea when studied in Ussing chambers in vitro. Again there was restoration of approximately 50% of the deficit in the chloride J R Soc Med 1997;90(Suppl. 31):43-46 Ion Transport Unit, National Heart & Lung Institute, Manresa Road, London SW3 6LR, England Correspondence to: Eric WFW Alton MRCP 43 abnormality. The exon 10 insertional mouse model does not show the increased sodium transport seen in man in the lower airways, rather this model demonstrates reduced transport of this ion. This abnormality was also improved towards normal values following gene transfer. As in the upper airways marked variability was seen. No signs of toxicity were seen in the respiratory tract.
This study and a similar one from the Oxford/ Cambridge group8 suggested that liposome-mediated CFTR gene transfer may be a practical option for initial studies of gene transfer into CF patients. We, therefore, undertook a number of preparatory studies in man in vivo to assess the feasibility of such a trial. We first assessed the safety aspects of nasal administration of DC-Cholesterol:DOPE9: Nasal potential difference (PD) provides a good index of tissue integrity and we, therefore, studied both sodium and chloride transport in these subjects prior to, and one and five days following, intranasal administration of the dose of liposome likely to be used in a study of gene transfer. No alterations were seen in any parameter in either group of subjects. Furthermore, no changes in spirometry resulted from this administration. Finally, we assessed whether the presence of liposomes would alter the growth or sensitivity of the resident bacteria present in the noses of CF subjects. Again no significant effects were seen, suggesting that topical administration of DC-Cholesterol may not produce deleterious effects in vivo in man. In order to assess the effects of CFTR gene transfer in man in vivo it was important to have in place a technique for the measurement of both the sodium and chloride defects. We, therefore, next assessed the optimal protocol for such a study10. In six CF subjects we compared the signal for chloride secretion produced either by perfusion of the fiagonists isoprenaline or terbutaline or by perfusion of a low chloride containing solution. A combination of sequential perfusion with low chloride followed by isoprenaline provided the optimal discrimination between CF and non CF subjects. With respect to sodium measurements, both the baseline PD as well as subsequent perfusion with amiloride provided a good measure of the absorption of this ion. This protocol is likely to be used in many of the forthcoming gene therapy trials for this disease.
With these studies in place we began the series of steps necessary to gain ethical permission for a human trial of liposome-mediated gene transfer to the nasal epithelium of CF patients in 199211. Essentially, four stages had to be gone through beginning with the Gene Therapy Advisory Committee. The safety aspects of the therapeutic product were assessed by the Medicine Control Agency, whilst the well-being of the investigators was supervised by the Advisory Committee on Gene Modification. Finally, the study was assessed by our local We obtained permission for the trial in early 1993 and then tackled the next hurdle of producing sufficient quantities of both DNA and liposome. For the former we are indebted to the Human Genome Resource Centre of Northwick Park who rapidly and efficiently produced the required amounts of DNA. With respect to the latter we chose to use DC-Cholesterol:DOPE for two reasons. Firstly, we had obtained experience using this liposome in the CF mouse study. Secondly, the Federal Drug Administration as well as the Recombinant Advisory Committee in the USA has approved the use of this agent for a human melanoma gene therapy trial conducted by Dr Gary Nabel. Professor Leaf Huang at the University of Pittsburgh, USA who first produced DC-Cholesteroll2, therefore agreed to produce the large quantities of liposome needed for the trial.
We began recruitment in July 1993, and studied 15 homozygous A 508 CF subjects, all pancreatic insufficient in a double-blind placebo controlled trial13. We used a CFTR cDNA driven by a SV40 promoter complexed with DC-Cholesterol in a ratio of 1:5 as in our study in CF mice. For ethical reasons we chose severely affected individuals with an FEV1 less than 40% predicted. Further, because of the theoretical risk of germ line transmission, and because CF men are infertile, we only studied male subjects for this trial. The study was conducted in two stages. Three subjects were randomized to 'low' dose DNA (10 ,ug per nostril) and three to 'medium' dose (100 ig per nostril). A further three received only liposome equivalent to that received by the medium dose group. These nine subjects were studied, the code broken and safety assessed. We then proceeded to the second stage in which three subjects were randomized to 'high' dose DNA (300 Mg per nostril) and a further three who received the increased dose of liposome alone. Application to both nostrils was through a commercially available pump spray which produced an aerosol of mass median diameter 60,m. Because of concerns that contact time with the nasal epithelium was an important factor in the efficiency of gene transfer, and because nasal mucociliary clearance is of the order of 10-15 min, we chose to administer the DNA-liposome complex in divided doses. For Stage 1, this was every 15 minutes over two and a half hours and for Stage 2, because of the much larger volumes, every 10min over approximately 7h. No sideeffects related to the administration procedure were noted. To study safety we assessed the patients clinically, asked them to keep a diary card and measured spirometry on each of the days we saw the subjects. These were 14 and seven days prior to, and on the day of gene transfer. Subsequently, we studied them at days 1, 3, 4, 5, 7, 11, 18 and 28 following administration. In addition we took chest radiographs and a large series of blood tests at the beginning and end of the Ethical Committee. 3 1 Vo u me 90 1 9 9 7 study period. Blood samples were also assessed on days one and four following gene transfer, looking respectively for acute toxicity and changes following our prediction for maximal gene expression. We also took a nasal biopsy from one nostril on day four for histological assessment. With regard to efficacy, half of this biopsy as well as nasal brushings taken on the same occasion were assessed for vector-specific mRNA using conventional polymerase chain reaction (PCR) techniques. Further, we measured nasal PD using the Protocol outlined above on each of the days except day four, when the nasal biopsy was taken.
There were no clinical abnormalities seen, nor changes on the radiographs or in the blood tests. The histological assessment was performed in a blinded manner and no differences were seen in the DNA-or liposome-only groups with respect to conventional histology, neutrophil elastase, macrophage number or CD45 + T-lymphocytes. One subject, who received low dose DNA showed a chronic subepithelial lymphocytic infiltrate. It is likely that if sufficient biopsies are taken from these patients with chronic nasal infection, such changes will be revealed; however, we cannot disprove that this related to the treatment received.
Of the nasal brushings only one was positive for plasmid DNA (not mRNA); this was from a high dose subject. Interestingly, however, five of the eight available biopsies from the DNA treated subjects were positive both for DNA and mRNA. To summarize the measurements of nasal PD, the response to the low chloride perfusion showed a significant increase of approximately 20% from CF towards non-CF values. In some cases these reached normal values but overall there was marked variability. The response to isoprenaline was virtually unchanged following gene transfer. Responses related to sodium transport were less marked than for chloride, although just detectable. The changes in the ion transport parameters were maximal around day three and had returned to pretreatment values by day seven following gene transfer.
It is perhaps worth considering these data in the context of the other CF gene therapy trials being undertaken. No other liposome-based study has yet been reported, although three others are underway or recently completed (Alabama, USA, Edinburgh and Oxford/Cambridge, UK). Six trials of adenoviral-mediated CFTR gene transfer are also underway (Crystal-NIH, Cornell, Welsh-Iowa, Wilson-Pennsylvania, Boucher-North Carolina, Whitsett-Cincinnati, USA, Pavarani-Transgene, France). Two of these have reported preliminary findings. The first of these was the Iowa group14 who looked at three subjects in a non-blinded uncontrolled study. They showed correction of both the sodium and the chloride abnormalities in the nasal epithelium for a period of approximately 2-3 weeks following single application. Conventional RT-PCR failed to show the presence of mRNA, but a modification of this process could subjects. The Crystal study15 assessed both nasal and lower airway application in four subjects. No measures of CFTR function were included, but mRNA was present in one of the four nasal specimens and CFTR protein in one of the nasal and one of the bronchial specimens. However, one of the patients (who received the highest dose) developed hypotension, fever and respiratory symptoms suggestive of an inflammatory reaction within the lungs. These changes were suggested to relate to an increase in interleukin-6 and resolved completely over a period of one month. Thus, these adenoviral studies are beginning to define a therapeutic window with respect to dose-efficacy-safety considerations. It is likely that many of the problems encountered in these studies relate to immunological reactions focused on the viruses' coat proteins, and strenuous efforts are being made to prevent the virus from producing these proteins. It is likely, therefore, that safer adenoviral-mediated gene transfer will be possible with these second generation viruses. A further potential problem with their use is the effect of neutralizing antibodies in limiting the efficacy of repeated administration. Whilst this has yet to be studied in human trials, it has clearly been demonstrated in some, if not all, animal studies. This is of relevance since neither liposomenor adenovirus-mediated gene transfer will produce stable integration of the gene into the genome and repeated administration will be needed.
With regard to efficacy most groups agree that there are similar problems to those seen in our CF mouse study. Thus, gene transfer is very variable and despite relatively large quantities of DNA is fairly inefficient. Additionally, chloride-related abnormalities appear easier to correct than the sodium defect. The clinical relevance of these findings is presently difficult to judge. Whether the chloride or sodium defect is the more important to correct is unknown. Further the degree of correction need for clinical benefit is also uncertain. However, recent studies suggest that approximately 5% of cells corrected may be sufficient to produce normal ion transport properties within an epithelial sheet. Whilst clearly transfection efficiency needs to be improved, we may not be very far from the necessary in vivo requirement.
With regard to future studies we have recently begun a lung trial on a similar basis to the nasal studies described above. This is principally to assess safety and also to learn how to measure gene transfer efficacy in this more difficult part of the airways. In parallel with this we are undertaking in vitro laboratory studies to try to improve transfection efficiency using liposomes. Promising ideas will then be taken through a further nose trial prior to use in the lungs of CF patients. During this time further data will become available on the use of adenovirus for gene transfer. It is likely that neither of the present systems will be ideal for 4 demonstrate the appropriate message in two of the three 45 large phase III studies in man, and a combination of the two may eventually provide a better gene transfer agent.
